BridgeBio Pharma Inc. announced that the first asymptomatic participant with a known pathogenic transthyretin (TTR) variant, that may lead to transthyretin amyloid disease (either cardiomyopathy, ATTR-CM, polyneuropathy, ATTR-PN,… read more.
Sana Biotechnology, a company focused on changing the possible for patients through engineered cells, announced an upcoming podium presentation highlighting ongoing clinical data from the investigator-sponsored, first-in-human study… read more.
Atara Biotherapeutics , a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases,… read more.
In the global, Phase 3 DeLLphi-304 clinical trial1 evaluating Imdelltra® (tarlatamab-dlle) treatment for patients with small cell lung cancer (SCLC) who progressed on or after a single line… read more.
NICE (UK): Leniolisib is recommended, within its marketing authorisation, for treating activated phosphoinositide 3‑kinase delta syndrome (APDS) in people 12 years and over. Leniolisib is recommended only if… read more.
KalVistA Pharmaceuticals Inc. announced the acceptance of six scientific abstracts at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 taking place in Glasgow, United Kingdom… read more.
Fresenius announced that the Committee for Medicinal Products for Human Use (CHMP) of the EMA has issued a positive opinion for its denosumab biosimilar candidates, Bomyntra and Conexxence… read more.
Connect Biopharma Holdings Limited (a clinical-stage biopharmaceutical company focused on transforming acute and chronic care of asthma and chronic obstructive pulmonary disease (COPD), today announced two oral presentations… read more.
Liquidia Corporation announced that the FDA has approved Yutrepia (treprostinil) inhalation powder, a prostacyclin analog for adults with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial… read more.
Tonix Pharmaceuticals Holding Corp. announced a poster presentation at the Annual European Congress of Rheumatology (EULAR) 2025, being held June 11-14, 2025, in Barcelona, Spain. Details on the… read more.
Gilead Sciences, Inc., following the recent acquisition of CymaBay Therapeutics, Inc., announced two-year interim results from the ongoing ASSURE study of investigational seladelpar for the treatment of primary… read more.
Sobi will have a strong scientific presence at this year’s ERA congress in Vienna (4-7 June) with a total of eight presentations: six oral presentations and two posters…. read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
